A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers ... disease (COPD). Sales of Breztri ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere ... Eligible patients had COPD, were ages 40 or older, and were new initiators of these inhalers from 2021 to 2023.

Drug Interactions with Strong ... Budesonide: Following inhaled administration of Breztri Aerosphere in subjects with COPD, Cmax occurred within 20 to 40 minutes. Steady state is estimated to ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance inhalers and offers medication management services, according to results ...

are primarily treated using inhaled medications. In a new study, "Prevalence of Critical Errors and Insufficient Peak Inspiratory Flow in Patients Hospitalized With COPD in a Department of General ...

Key drivers include Breztri Aerosphere (budesonide ... to target specific inflammatory pathways in COPD, a space previously dominated by inhaled therapies. AstraZeneca’s Fasenra, an IL-5 ...